ORPHA:98837
Acute biphenotypic leukemia
Publications
249
Trials
39
Interventional, condition-specific
Researchers
1,398
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
249 matched papers (103 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
39 matched on ClinicalTrials.gov (8 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-27
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
249
249 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
249 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
103 in the last 10 years · low confidence
Phrase hits: 249 · MeSH hits: 0
Who's working on it?
1,398
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Huang F6 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 02Sun J6 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 03Xuan L6 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 04Fan Z5 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 05Xu N5 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 06Liu H4 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC - 07Liu Q4 papers · 2023
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. liuqifa628@163.com.
Papers in Europe PMC - 08Wang Y4 papers · 2022
Department of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
Papers in Europe PMC - 09Zhang Y4 papers · 2025
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Papers in Europe PMC - 10Zhou H4 papers · 2024
Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
39
interventional trials for this specific condition
39 interventional trials matched this specific condition name; 8 currently recruiting in our sample.
Data as of 9 September 2026
39 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 96.7th percentile).
low confidence · 96.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
39 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT02727803·RECRUITING·Personalized NK Cell Therapy in CBT
Confirmed·Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Biphenotypic Leukemia · Acute Lymphoblastic Leukemia · Acute Lymphoblastic Leukemia in Remission·Matched via name phraseBoth providers judged relevant.
- NCT07710781·NOT YET RECRUITING·Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Confirmed·Conditions: Hematologic Malignancy · Acute Leukemia · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia·Matched via name phraseBoth providers judged relevant.
- NCT04797767·RECRUITING·Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Confirmed·Conditions: Acute Biphenotypic Leukemia · Acute Myeloid Leukemia · Mixed Phenotype Acute Leukemia · Myeloid Neoplasm·Matched via name phraseBoth providers judged relevant.
- NCT03326921·RECRUITING·HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Confirmed·Conditions: Juvenile Myelomonocytic Leukemia · Recurrent Acute Biphenotypic Leukemia · Recurrent Acute Undifferentiated Leukemia · Recurrent Childhood Acute Lymphoblastic Leukemia·Matched via name phraseBoth providers judged relevant.
- NCT04047641·RECRUITING·Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Uncertain·Conditions: Acute Myeloid Leukemia · Blasts 20 Percent or More of Bone Marrow Nucleated Cells · High Risk Myelodysplastic Syndrome · Recurrent Acute Biphenotypic Leukemia·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT02115295·RECRUITING·Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Confirmed·Conditions: Acute Biphenotypic Leukemia · Acute Myeloid Leukemia · Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Blasts 10 Percent or More of Bone Marrow Nucleated Cells·Matched via name phraseBoth providers judged relevant.
- NCT03683433·RECRUITING·Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Confirmed·Conditions: Acute Bilineal Leukemia · Acute Biphenotypic Leukemia · Chronic Myelomonocytic Leukemia · IDH2 Gene Mutation·Matched via name phraseBoth providers judged relevant.
- NCT03779854·RECRUITING·Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Confirmed·Conditions: Acute Biphenotypic Leukemia · Acute Leukemia · Acute Leukemia of Ambiguous Lineage · Acute Lymphoblastic Leukemia·Matched via name phraseBoth providers judged relevant.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 3 · after dedupe 3 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 2 · fetched 2026-07-27
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
- isrctn·ISRCTN12500962·No longer recruiting·International collaborative treatment protocol for infants under age one with acute lymphoblastic or biphenotypic leukemia
Uncertain — At least one provider returned uncertain or parent-category.
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Acute biphenotypic leukemia — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Acute biphenotypic leukemia"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Acute biphenotypic leukemia"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 39 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- No Orphanet definition and no Mondo IDs — likely taxonomy scaffolding; confidence capped at low
Ingested 2026-07-26T01:51:29.779Z